Search results
Showing 3301 to 3315 of 7691 results
How we collect and use your personal information, and your rights under data protection legislation
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
Our publication scheme lists all of the information we routinely make available, and where you can find it. We publish most of the information below...
NICE transparency of spend
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members
The different types of health, public health and social care information provided by NICE.
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals. Read the appeal panel
Find out more about the progress made in implementing NICE guidance on diagnostic pathology
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
We work with an independent indicator advisory committee (IAC) to develop indicators suitable for inclusion in the Quality and Outcomes Framework...
Decision aid for Intrabeam radiotherapy system for adjuvant treatment of early breast cancer, TA501 c NICE 2018. All rights reserved. Subject to...
A new model for evaluating and purchasing antimicrobials in the UK
Antimicrobial resistance (AMR) is an urgent global challenge. It causes around 700,000 deaths each year globally . That number is predicted to rise to
Diabetes: blood pressure (without moderate or severe frailty)
This indicator has been updated and replaced by NICE indicator 249.
Atrial fibrillation: pulse rhythm assessment in people at risk
This indicator has been withdrawn following National Screening Committee recommendations and ongoing research.